Molecular determinants of occult metastatic tumor cells in bone marrow

Clinical Breast Cancer

Volumn 2, Issue 3, 2001, Pages 222-228

  Pantel, Klaus ^a   Braun, Stephan ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cytokeratin; Epithelial cancer; HER2 neu, p53 Micrometastases

Indexed keywords

CARBOPLATIN; CD45 ANTIGEN; CELL ADHESION MOLECULE; CYTOTOXIC ANTIBODY; CYTOTOXIC ANTIBODY ABL 364; EDRECOLAMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; HLA ANTIGEN CLASS 1; IFOSFAMIDE; KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; PROTEIN P120; TRANSFERRIN; UNCLASSIFIED DRUG; VIMENTIN; VINBLASTINE;

ARTICLE; BONE MARROW METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER RISK; CANCER SCREENING; CANCER STAGING; CELL CLONE; COLORECTAL CANCER; CONTROLLED STUDY; DISSEMINATED CANCER; DRUG MECHANISM; DRUG TARGETING; EPITHELIUM TUMOR; HUMAN; MAMMOGRAPHY; MINIMAL RESIDUAL DISEASE; OCCULT CANCER; ONCOGENE NEU; PATIENT MONITORING; PROGNOSIS; PROSTATE CANCER; STEM CELL TRANSPLANTATION; TUMOR CELL;

EID: 0035182699     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2001.n.025     Document Type: Article

References (64)

1. Detection of minimal disease in patients with solid tumors
2. Micrometastatic cancer cells in bone marrow: In vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies
3. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow
4. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer
5. Micrometastases in bone marrow in patients with primary breast cancer: Evaluation as an early predictor of bone metastases
6. Monoclonal antibody detection of carcinoma cells in bone marrow biopsy specimens from breast cancer patients
7. Use of monoclonal antibody MBr1 to detect micrometastases in bone marrow specimens of breast cancer patients
8. Immunohistochemical staining of bone marrow biopsies for detection of occult metastasis in breast cancer
9. The prognostic significance of marrow micrometastases in women with early breast cancer
10. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases
11. Detection of micrometastatic tumor cells in bone marrow of breast carcinoma patients
12. Monoclonal antibody LICR-LON-M8 does not predict the outcome of operable breast cancer
13. Comparative analyses of bone marrow micrometastases in breast and gastric cancer
14. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: Results of a 3-year median follow-up
15. Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status
16. Detection of Cytokeratin (CK) 18 Positive Cells in the Bone Marrow (BM) of Breast Cancer Patients - No Prediction of Bad Outcome
17. Outcome of primary-breast-cancer patients with micrometastases: A long-term follow-up study
18. Prognostic value of bone marrow biopsy in operable breast cancer patients at the time of initial diagnosis: Results of a 20-year median follow-up
19. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy
20. Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients
21. Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery
22. Induction of tumour cell shedding into effluent venous blood breast cancer surgery
23. Tumor-antigen heterogeneity of disseminated breast cancer cells: Implications for immunotherapy of minimal residual disease
24. Establishment of micrometastatic carcinoma cell lines: A novel source of tumor cell vaccines
25. Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumour cells
26. Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells
27. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells
28. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67
29. Identification and characterization of a human proliferation-associated nucleolar antigen with a molecular weight of 120,000 expressed in early G1 phase
30. Detection, characterization and tumorigenicity of disseminated tumor cells in human bone marrow
31. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer
32. Prognostic significance of c-erbB-2 expression in node negative breast cancer
33. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading
34. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis
35. Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis
36. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: Immunohistological assessment correlates with gene amplification
37. Isolation of blood-borne epithelium-derived c-erbB-2 oncoprotein-positive clustered cells from the peripheral blood of breast cancer patients
38. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
39. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory treatment
40. Addition of Herceptin™ (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: Randomized, multinational trial
41. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2-overexpressing metastatic breast cancer
42. Chromosomal aneusomies in prostate cancer marrow micrometastases
43. Low frequency epithelial cells in bone marrow aspirates from prostate carcinoma patients are cytogenetically aberrant
44. Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells
45. Clinical importance of analysing malignant tumours of uncertain origin with immunohistological techniques
46. Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers
47. Regulation and functional role of MHC expression in tumors
48. Cell adhesion in invasion and metastasis
49. Molecular aspects of the metastatic cascade
50. Desmosomes and hemidesmosomes: Constitutive molecular components
51. The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: Its biochemical nature, tissue distribution and recognition by different monoclonal antibodies
52. Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: Establishment of working models for human micrometastases
53. Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer
54. Efficient immortalization of luminal epithelial cells from human mammary gland by introduction of simian virus 40 large tumor antigen with a recombinant retrovirus
55. Immunocytochemical monitoring of micrometastatic disease: Reduction of prostate cancer cells in bone marrow by androgen deprivation
56. Antibodies as cytotoxic therapy
57. Monoclonal antibody therapy with edrecolomab in breast cancer patients: Monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow
58. Reduction of metastatic carcinoma cells in bone marrow by intravenously administered monoclonal antibody: Towards a novel surrogate test to monitor adjuvant therapies of solid tumours
59. Biological activity in the human system of isotype variants of oligosaccharide-Y-specific murine monoclonal antibodies
60. Adoptive immunotherapy with monoclonal antibody 17-1A to reduce minimal residue in breast cancer patients after high-dose chemotherapy
61. Persistence of isolated tumor cells in patients with breast cancer after sequential high-dose therapy with peripheral blood stem cell transplantation
62. Standardisation of the immunocytochemical detection of cancer cells in bone marrow and blood: I. Establishment of objective criteria for the evaluation of immunostained cells
63. Minimal residual epithelial cancer: Diagnostic approaches and prognostic relevance
64. p53 immunostaining of megakaryocytes is preferentially observed in patients with epithelial malignancies